The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The overlooked pandemic of antimicrobial resistance
Open accessAbstract
As COVID-19 rages on, the pandemic of antimicrobial resistance (AMR) continues in the shadows. The toll taken by AMR on patients and their families is largely invisible but is reflected in prolonged bacterial infections that extend hospital stays and cause needless deaths. Moreover, AMR disproportionately affects poor individuals who have little access to second-line, more expensive antibiotics that could work when first-line drugs fail. Previous attempts have been made to accurately estimate the global burden of AMR, both to focus policy makers on the extent of the problem and to identify geographical areas with the greatest burden. These estimates have been challenged by unreliable data on resistance and infections and the difficulty of attributing burden to AMR specifically. Patients with longer hospitals stays are more likely to have resistant pathogens than those with shorter stays. Is it AMR that causes these longer hospital stays or is it just that patients who stay longer happen to pick up drugresistant infections? How can we distinguish between patients who died with resistant pathogens from those who died of resistant pathogens? In The Lancet, Christopher Murray and colleagues present their ambitious effort to address the question of the global burden of AMR. The authors estimated disease burden for 23 pathogens and 88 pathogen– drug combinations in 204 countries and territories in 2019 on the basis of two counterfactual scenarios: one in which all drug-resistant infections were replaced by drug-susceptible infections, and one in which all drugresistant infections were replaced by no infection. Using this method, the study directly addresses the difference between burden associated with resistance, and burden attributable to resistance. Murray and colleagues estimated a median of 1·27 million (95% uncertainty interval 0·911–1·71) deaths in 2019 directly attributable to resistance, a value that is nearly the same as global HIV deaths (680 000) and malaria deaths (627 000) combined, and ranks behind only COVID-19 and tuberculosis in terms of global deaths from an infection. The study’s estimate of 4·95 million (3·62–6·57) deaths associated with bacterial AMR globally in 2019 indicates that there are substantial gains to be made from preventing infections in the first place. Of the major bacterial pathogens covered in this study, only pneumococcal pneumonia is preventable through vaccination. Preventive vaccines against viral pathogens including influenza, respiratory syncytial virus, and rotavirus could be effective in reducing the need for treatment, thereby reducing inappropriate antibiotic consumption. In high-income countries, improved water and sanitation, public health, and hospital hygiene have been the primary ways in which infections have been controlled, but these methods have been difficult to implement in resource-poor settings despite economic progress. Ironically, the burden of resistance partly reflects the insufficient access to antibiotics. The problem of excessive and inappropriate use of antibiotics co-exists with the problem of insufficient access even in the same geographical areas. Pneumococcal pneumonia is easily treatable with antibiotics, but the burden estimated by Murray and colleagues reflects the lack of access to even inexpensive drugs such as penicillin. Some of the AMR burden in sub-Saharan Africa is probably due to inadequate access to antibiotics and high infection levels, albeit at low levels of resistance, whereas in south Asia and Latin America, it is because of high resistance even with good access to antibiotics. Over two-thirds of attributable deaths were due to resistance to first-line antibiotics including fluoroquinolones and β-lactam antibiotics (carbapenems, cephalosporins, and penicillins). Published Online January 20, 2022 https://doi.org/10.1016/ S0140-6736(22)00087-3
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Self-citationWill 10 Million People Die a Year due to Antimicrobial Resistance by 2050?
de Kraker, M. E. A., Stewardson, A. J., & Harbarth, S. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002184 · Cited by 1,596
Access to effective antimicrobials: a worldwide challenge
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00474-2 · Cited by 1,465
Self-citationTeillant, A., Gandra, S., Barter, D., Morgan, D. J., & Laxminarayan, R. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00270-4 · Cited by 379
Self-citationEconomic burden of antibiotic resistance: how much do we really know?
Gandra, S., Barter, D. M., & Laxminarayan, R. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12798 · Cited by 281
Self-citationDieleman, J. L., Haakenstad, A., Micah, A., Moses, M., Abbafati, C., Acharya, P., Adhikari, T. B., Adou, A. K., Ahmad Kiadaliri, A., Alam, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30698-6 · Cited by 168
Childhood vaccines and antibiotic use in low- and middle-income countries
Lewnard, J. A., Lo, N. C., Arinaminpathy, N., Frost, I., & Laxminarayan, R. (2020) · Nature · doi:10.1038/s41586-020-2238-4 · Cited by 152
Self-citationAndrejko, K. L., Ratnasiri, B. M., Hausdorff, W. P., Laxminarayan, R., & Lewnard, J. A. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00064-1 · Cited by 109
Self-citationLewnard, J. A., McQuade, E. T. R., Platts-Mills, J. A., Kotloff, K. L., & Laxminarayan, R. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008520 · Cited by 51
Self-citation
Cited by
Lateral flow test engineering and lessons learned from COVID-19
Budd, J., Miller, B. S., Weckman, N. E., Cherkaoui, D., Huang, D., Decruz, A. T., Fongwen, N., Han, G.-R., Broto, M., Estcourt, C. S., et al. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00007-3 · Cited by 308
International Consensus on a Dental Antibiotic Stewardship Core Outcome Set
Thompson, W., Teoh, L., Pulcini, C., Sanderson, S., Williams, D., Carter, V., Pitkeathley, C., & Walsh, T. (2023) · International Dental Journal · doi:10.1016/j.identj.2023.03.006 · Cited by 28
“In 2019, more people died from infections that were resistant to antibiotics than from HIV and malaria combined.(2) The burden is increasing rapidly and, without appropriate intervention, by 2050 10 million deaths each year are expected from resistant infections: more than from cancer.”
Background
Metadata
- Authors
- Laxminarayan, R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 399
- Issue
- 10325
- Pages
- 606-607
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4205969323
- Cited by
- 325
- References
- 10
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The overlooked pandemic of antimicrobial resistance. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00087-3
- The paper
- Laxminarayan, R. (2022). The overlooked pandemic of antimicrobial resistance. The Lancet. https://doi.org/10.1016/s0140-6736(22)00087-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.